Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $44.8M | $52.3M | $25.2M |
| Revenue growth | — | 16.8% | -51.8% |
| Operating income | -$78.5M | -$88.9M | -$96.0M |
| Operating margin | -175.4% | -170.0% | -380.9% |
| Net income | -$68.3M | -$78.1M | -$87.9M |
| Net margin | -152.5% | -149.3% | -348.5% |
| EPS (diluted) | -$20.05 | -$2.36 | -$2.36 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$91.4M | -$109M | -$88.9M |
| Capital expenditures | $9.81M | $3.11M | $574K |
| Free cash flow | -$101M | -$112M | -$89.5M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $141M | $27.4M | $41.7M |
| Total assets | $365M | $325M | $221M |
| Total liabilities | $150M | $89.7M | $62.5M |
| Shareholders' equity | -$136M | $235M | $159M |
| Retained earnings | -$145M | -$223M | -$311M |
| Shares (wtd avg diluted) | 3.40M | 33.0M | 37.3M |
Every figure is extracted from Metagenomi Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.